SUBSCRIBE
SUBSCRIBE
News   Policy

Amgen’s (JOBS) Bone Drug May Face Delays In FDA Decision

October 16, 2009 | 
1 min read
Bookmark and Share

NEW YORK (Dow Jones)--Biotech investors had circled Oct. 19 as the day that Amgen Inc.'s (AMGN) osteoporosis drug denosumab gets approved, but they may have to wait longer.
Regulatory
Amgen Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Collage of gavel, safety cones and roadblock
Legal
Court Suspends Mass Layoffs at HHS, Rules Staff Cuts Likely Unlawful
July 2, 2025
 · 
2 min read
 · 
Tristan Manalac
Government
RFK Jr. Eyes Changes to Vaccine Injury Compensation Program
July 2, 2025
 · 
2 min read
 · 
Tristan Manalac
Yellow warning sign symbol or alert safety danger caution illustration icon security message and exclamation triangle information icon on attention traffic background with secure alarm. 3D render.
Regulatory
FDA Mulls ‘Regulatory Action’ on Argenx’s Vyvgart Hytrulo Over Severe Safety Concerns
July 2, 2025
 · 
2 min read
 · 
Tristan Manalac
Podcast
CAR T Expands, M&A Ticks Up, Two Psychedelics Read Out, and the Supreme Court Rules on PrEP
July 2, 2025
 · 
1 min read
 · 
Heather McKenzie